TD Cowen raised the firm’s price target on Tandem Diabetes (TNDM) to $28 from $25 and keeps a Buy rating on the shares. The firm updated its model to map the multiple variables driving its future growth/profitability outlook.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Leveraging Rx Channel Shift and Mobi Tubeless Launch to Drive Sustainable Growth at Tandem Diabetes Care
- Citi adds ‘upside 90-day catalyst watch’ on Tandem Diabetes
- Micron downgraded, Five Below upgraded: Wall Street’s top analyst calls
- Truist upgrades Tandem Diabetes to Buy on growing conviction in upside potential
- Tandem Diabetes upgraded to Buy from Hold at Truist